110
Views
11
CrossRef citations to date
0
Altmetric
Review

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

, , &
Pages 9-15 | Published online: 15 Dec 2014

References

  • GattaGRossiSCapocacciaRCancer burden estimates and forecasts: uses and cautionsTumori201399343944324158074
  • ChouaidCAtsouKHejblumGVergnenegreAEconomics of treatments for non-small cell lung cancerPharmacoeconomics200927211312519254045
  • IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol201113746047121775273
  • NeubauerMAHovermanJRKolodziejMCost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community settingJ Oncol Pract201061121820539725
  • LewisJRLipworthWLKerridgeIHDayROThe economic evaluation of personalised oncology medicines: ethical challengesMed J Aust2013199747147324099207
  • BesseBAdjeiABaasPPanel Members2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseAnn Oncol20142581475148424669016
  • BrownTBolandABagustAGefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2717921047494
  • BongersMLCoupéVMJansmaEPSmitEFUyl-de GrootCACost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic reviewPharmacoeconomics2012301173422201521
  • BrownTPilkingtonGBagustAClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationHealth Technol Assess201317311278
  • NeymarkNLianesPSmitEFvan MeerbeeckJPEconomic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancerPharmacoeconomics200523111155116616277550
  • ThongprasertSPermsuwanURuengornCCharoentumCChewaskulyongBCost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancerAsia Pac J Clin Oncol20117436937522151987
  • PimentelFLBhallaSLaranjeiraLGuerreiroMCost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancerLung Cancer200652336537116650499
  • NovelloSKielhornAStynesGItalian Lung Cancer Project InvestigatorsCost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyLung Cancer200548337938715893007
  • SchillerJTildenDAristidesMRetrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeLung Cancer200443110111214698544
  • KleinRMuehlenbeinCLiepaAMBabineauxSWielageRSchwartzbergLCost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancerJ Thorac Oncol20094111404141419786904
  • ShahMWinfreeKBPetersonPGruschkusSKEaddyMGreenMRCost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient settingLung Cancer201382112112723973203
  • TadaHMatsuiSKawaharaMHosoeSHamadaCFukushimaMEfficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experienceEur J Cancer Care (Engl)200817212012618302648
  • ManiadakisNFragoulakisVPallisAPrezerakosPGeorgouliasVEconomic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in GreeceLung Cancer200758227528117688969
  • HornLVisbalALeighlNBDocetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomicsDrugs Aging200724541142817503897
  • ReaumeMNLeighlNBMittmannNEconomic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)Lung Cancer201382111512023962449
  • Le LayKMyonEHillSComparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS systemEur J Health Econ20078214515117333088
  • ChouaidCLe CaerHLocherCGFPC 0504 TeamCost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)BMC Cancer201212130122817667
  • ChouaidCLe CaerHCorreRCost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505)Clin Lung Cancer201314210310722682669
  • WangSPengLLiJA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerPLoS ONE201383e5591723520448
  • HandorfEAMcElligottSVachaniACost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lungJ Oncol Pract20128526727423277762
  • de Lima LopesGJrSegelJETanDSDoYKMokTFinkelsteinEACost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lungCancer201211841032103921792863
  • LeeVWSchwanderBLeeVHEffectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong KongHong Kong Med J201420317818624281768
  • DjalalovSBecaJHochJSCost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancerJ Clin Oncol201432101012101924567430
  • ChouaidCBorgetIVergnenegreATarget therapies in non-small-cell lung cancer management: no cost-effective strategies?J Clin Oncol Epub982014
  • AhnMJTsaiCMHsiaTCCost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and TaiwanAsia Pac J Clin Oncol20117Suppl 2223321585705
  • GoulartBRamseySA trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancerValue Health201114683684521914503
  • GiulianiGGrossiFde MarinisFWalzerSCost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in ItalyLung Cancer201069Suppl 1S11S1720727457
  • ChienCRShihYCChun -RuCYa-ChenTSEconomic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)Clinicoecon Outcomes Res2012420120822870040
  • BischoffHGHeigenerDFWalzerSNuijtenMCosts of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyLung Cancer20101S18S2320727458
  • StanisicSBischoffHGHeigenerDFSocietal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Lung Cancer201069Suppl 1S24S3020727459
  • KleinRWielageRMuehlenbeinCCost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancerJ Thorac Oncol2010581263127220581708
  • ZhuJLiTWangXGene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysisBMC Cancer20131313923360224
  • ZengXPengLLiJCost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care systemClin Ther2013351546523328269
  • ZengXLiJPengLEconomic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysisPLoS ONE201492e8888124586426
  • DicksonRBagustABolandAErlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisalPharmacoeconomics201129121051106221967156
  • Lyseng-WilliamsonKAErlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancerPharmacoeconomics2010281759220014878
  • NuijtenMJde Castro CarpeñoJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer201276346547122153602
  • WalleserSRayJBischoffHMaintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeClinicoecon Outcomes Res2012426927523028234
  • VergnenègreARayJAChouaidCCross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerClinicoecon Outcomes Res20124313722347803
  • GreenhalghJMcLeodCBagustAPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancerHealth Technol Assess201014Suppl 2333921047489
  • Matter-WalstraKJoergerMKühnelUSzucsTPestalozziBSchwenkglenksMCost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care systemValue Health2012151657122264973
  • SimondsNIKhouryMJSchullySDComparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospectsJ Natl Cancer Inst20131051392993623661804
  • Uyl-de GrootCAMcDonnellJTen VeldeGRadiceDGroenHJCost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain modelTher Clin Risk Manag20062331732318360607